Xigduo XR approved in China for adults with type-2 diabetes
Approval makes Xigduo XR the only once-daily fixed-dose combination of an SGLT2 inhibitor and metformin hydrochloride extended release in China.AstraZeneca’s Xigduo XR (dapagliflozin and metformin hydrochloride extended-release), a once-daily fixed-dose combination, has been approved by China’s National Medical Products Administration (NMPA) for the treatment of adults with type-2 diabetes (T2D) as an adjunct to diet and exercise to improve glycaemic control. Xigduo XR combines two anti-hyperglycaemic agents with complementary mechanisms of action: dapagliflozin (trade name, Forxiga), a